Best Healthcare Stocks this May 2026

Eli Lilly (LLY) stands out with remarkable growth, soaring 386.99% over the past five years, driven by its innovative diabetes and obesity treatments. Although it offers a modest dividend yield of 0.60%, the stock is backed by strong analyst recommendations, with a consensus rating of Buy and a 12-month price target range of $985 to $1,350. Given its strategic focus on expanding manufacturing capabilities and late-stage programs, Eli Lilly presents an attractive opportunity for investors seeking long-term growth.

Eli Lilly (LLY) has a consensus rating of Buy from 18 analysts, with 39% recommending a Strong Buy and 50% recommending a Buy.

Eli Lilly could potentially increase its annual sales by nearly $60 billion by 2030, more than doubling its current trailing-12-month revenue of approximately $53.2 billion.

Given its significant manufacturing investments and strong revenue growth, Eli Lilly may be well-positioned for a stock split in 2026.

The stock's decline is attributed to concerns that the market for obesity drugs may be smaller than expected and heightened competition for key products like Zepbound.

Vertex Pharmaceuticals (VRTX) stands out in the biotech sector with its leadership in cystic fibrosis treatments and innovative CRISPR gene therapy aimed at addressing pain and kidney diseases. Despite a recent one-year return of -12.65%, analysts remain optimistic, with a consensus Buy rating and a median 12-month price target of $558.00, indicating strong long-term growth potential driven by a robust pipeline and favorable market dynamics.

Vertex Pharmaceuticals (VRTX) has a consensus rating of Buy from 22 analysts, with 36% recommending a Strong Buy, 50% a Buy, and 14% suggesting a Hold.

Vertex is considered a compelling long-term investment due to its strong regulatory catalysts, expanding pipeline, solid financial health, and favorable market conditions.

Vertex's stock has declined 4.8% recently due to concerns about the commercial potential of its new drugs and broader issues like drug pricing and reimbursement.

AbbVie (ABBV) stands out as a pharmaceutical leader, boasting a robust drug pipeline and a solid dividend yield of 3.23%. With impressive long-term growth potential, analysts project that key products like Skyrizi and Rinvoq could contribute significantly to sales, reaching at least $32 billion by 2030. Currently, the stock has a median 12-month price target of $259, supported by strong analyst ratings including Overweight from Piper Sandler and Guggenheim.

Warren Buffett completely sold his stake in AbbVie Inc. between Q1 2021 and Q1 2022.

AbbVie projects full-year 2025 sales of $17.3 billion for its drug, with analysts expecting combined sales of Skyrizi and Rinvoq to reach at least $32 billion by 2030.

Intuitive Surgical (ISRG) stands out as a leader in robotic-assisted surgery with its innovative da Vinci system and the expanding Ion biopsy tool. Despite experiencing a 1-year return of -6.36%, the company has delivered an impressive 67.63% return over the past five years, indicating strong long-term growth potential. Analysts maintain a consensus rating of "buy," with a median price target of $618, reflecting confidence in the company’s future, particularly as it anticipates a 13.5% to 15.5% growth in da Vinci procedures by 2026.

Intuitive Surgical stock has a consensus rating of 'buy,' supported by 48 buy ratings, 16 hold ratings, and 1 sell rating.

Intuitive Surgical expects worldwide da Vinci procedure growth of 13.5% to 15.5% in 2026, with a non-GAAP gross profit margin between 67.5% and 68.5% of revenue.

Intuitive Surgical's year-over-year cash flow growth is 15.8%, significantly higher than the industry average of 0.8%.

A Discounted Cash Flow analysis indicates that Intuitive Surgical may be overvalued by 27.7%.